SCHEMBL6480089

SCHEMBL6480089

COc1cc(Nc2ncnc(-c3cccnc3NCCCN)n2)cc(OC)c1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 2/20 0.69
KDR P35968 3/20 0.53
FGFR3 P22607 10/20 0.52
FGFR2 P21802 9/20 0.52
IGF1R P08069 2/20 0.47
STK17A Q9UEE5 2/20 0.46
STK17B O94768 1/20 0.46
AURKB Q96GD4 1/20 0.45
PRKD3 O94806 1/20 0.45
EGFR P00533 1/20 0.45
PRKCG P05129 1/20 0.45
PRKCB P05771 1/20 0.45
LCK P06239 1/20 0.45
PRKCA P17252 1/20 0.45
PRKCH P24723 1/20 0.45
PRKCI P41743 1/20 0.45
ZAP70 P43403 1/20 0.45
PRKCE Q02156 1/20 0.45
PRKCQ Q04759 1/20 0.45
PRKCZ Q05513 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2325736 0.82 TEK (0.66) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL6481339 0.81 TEK (0.72) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL6480986 0.81 TEK (0.74) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL14214552 0.81 TEK (0.81) TEKKDRFGFR3FGFR2AURKB
SCHEMBL14214742 0.80 TEK (0.68) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL6479711 0.80 TEK (0.73) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL14214551 0.79 TEK (0.78) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL14214554 0.79 TEK (0.74) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL14214743 0.78 TEK (0.65) TEKKDRFGFR3FGFR2IGF1R
SCHEMBL14214736 0.77 TEK (0.75) TEKKDRFGFR3FGFR2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA TEK 6/4885KDR 4/4885FGFR3 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.